IVIM & OLINK in Sarcoma

Recruiting now · Phase 2

Conditions studied: Soft Tissue Sarcoma

In brief

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Key facts

Study ID

NCT05950594

Run by

University Health Network, Toronto

People needed

145

Starts

2024-03-05

Expected to finish

2027-11-30

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Ability to understand and the willingness to sign a written informed consent document
• Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension

You may not qualify if…

• Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)

Where it is running

• University Health Network — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.